The Syrian hamster model was selected to study in vivo efficacy, as it is perhaps the only model permissive for the productive replication of all viruses used in the study.42, 43, 44, 45 The selected tumor model, HapT1 pancreatic carcinoma, enables the isolation of TILs for ex vivo amplification for use as an adoptive cell therapy (ACT).46 Here, LYPLA1 is linked to exocrine pancreatic carcinoma.